within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EM02_Copanlisib;

model Copanlisib
  extends Pharmacolibrary.Drugs.ATC.L.L01EM02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EM02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Copanlisib is a phosphatidylinositol-3-kinase (PI3K) inhibitor primarily used in the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. It is approved for intravenous administration and acts by inhibiting the PI3K-alpha and PI3K-delta isoforms, crucial in malignant B-cell survival and proliferation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with relapsed/refractory indolent B-cell lymphoma following intravenous infusion of copanlisib at 60 mg dose.</p><h4>References</h4><ol><li><p>Gerisch, M, et al., &amp; Granvil, C (2017). Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [. <i>Cancer chemotherapy and pharmacology</i> 80(3) 535–544. DOI:<a href=&quot;https://doi.org/10.1007/s00280-017-3383-9&quot;>10.1007/s00280-017-3383-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28714036/&quot;>https://pubmed.ncbi.nlm.nih.gov/28714036</a></p></li><li><p>Doi, T, et al., &amp; Ohtsu, A (2017). A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. <i>Cancer chemotherapy and pharmacology</i> 79(1) 89–98. DOI:<a href=&quot;https://doi.org/10.1007/s00280-016-3198-0&quot;>10.1007/s00280-016-3198-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27915408/&quot;>https://pubmed.ncbi.nlm.nih.gov/27915408</a></p></li><li><p>Liu, W, et al., &amp; Zhu, J (2022). A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma. <i>Cancer chemotherapy and pharmacology</i> 89(6) 825–831. DOI:<a href=&quot;https://doi.org/10.1007/s00280-022-04417-3&quot;>10.1007/s00280-022-04417-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35322287/&quot;>https://pubmed.ncbi.nlm.nih.gov/35322287</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Copanlisib;
